ArcticZymes Technologies (AZT)

[TekBot]

ArcticZymes and Austrian Centre of Industrial Biotechnology Extend Collaborative Research on use of Salt-Active Nucleases for Bionanoparticle Purification

Tromsø, Norway, May 28th, 2025 - ArcticZymes Technologies ASA (OSE: AZT), in
collaboration with the Austrian Centre of Industrial Biotechnology (acib), has
extended their joint research partnership for another three years, focusing on
…

Vis børsmeldingen

delivering significantly enhanced purification methods for bionanoparticles
(BNPs), critical for safer, more effective gene therapies, vaccines, and cancer
treatments.

The ongoing phase of the project, which began in April 2024, demonstrated that
focusing on the removal of chromatin rather than accessible forms of DNA, is
essential for improved purification of bionanoparticles. This key insight,
gained through the collaboration with acib, revealed that ArcticZymes’ M-SAN
enzyme is significantly more effective at digesting chromatin than conventional
nucleases. M-SAN also strongly performs under process-relevant, physiological
salt conditions, which is a big advantage when producing sensitive BNPs such as
lentiviral vectors. This advancement has enabled ArcticZymes to distinctly
differentiate its SAN portfolio from competition and highlight their unique
benefits to the bioprocessing community.

The extended collaboration will focus on proving the value of high-salt nuclease
treatments, leveraging the enzymes from ArcticZymes’ SAN family. It will also
develop improved methods for detecting and quantifying chromatin DNA since
existing assays fail to do this accurately. These efforts aim to create more
efficient, scalable, and cost-effective purification strategies for BNP-based
therapeutics. The extended collaboration also underscores ArcticZymes’ ongoing
commitment to innovation and practical solutions that meet customer needs.

This collaborative research continues to receive support from the COMET program,
which has awarded an additional EUR 100,000 to advance biotechnology innovation
through industry-academic partnerships. Moreover, the project includes the
training of a PhD candidate, contributing to the future talent pool and ensuring
continued advancement in bioprocessing technology and enzyme development.

Michael B. Akoh, CEO of ArcticZymes Technologies, commented:
“Collaborating with acib, one of the leading research groups in bioprocessing,
is instrumental in showing precisely how our nucleases best address customer
challenges. Together, we are enhancing biomanufacturing workflows for virus-like
particles, enabling our clients to optimize their processes, improve
efficiencies, and achieve more cost-effective and reliable outcomes.”

Dr. Mathias Drexler, CEO of acib, added:
“The partnership allows us to bridge fundamental research with real-world
bioprocessing needs. Working with ArcticZymes gives us access to innovative
enzymatic tools that perform under real production conditions. Their technology
plays a key role in shaping more effective and scalable solutions for the
biomanufacturing industry. Together, we are advancing purification strategies
that are both, scientifically sound and industry-relevant.”

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Its headquarters are based in Tromsø, Norway, at the SIVA Science Park.
ArcticZymes Technologies’ IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com

Kilde

[TekBot]

ArcticZymes Technologies AS - Mandatory notification of trade

Marit Sjo Lorentzen, VP Operations has on 3 June purchased 3.400 shares in
ArcticZymes Technoloiges ASA for NOK 16.00 per share. Following this transaction
holds Mrs. Lorentzen 28.731 shares and 135,000 options in the company.
…

Vis børsmeldingen

This information is subject to the disclosure requirements in articles 19 of the
Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the
Norwegian Securities Trading Act.

For additional information, please contact
Børge Sørvoll
CFO
+4795290187
ir@arcticzymes.com

Kilde

[TekBot]

ArcticZymes Technologies to present at Handelsbanken Small & Mid Cap Seminar 2025

(Tromsø, 04 June 2025) ArcticZymes Technologies ASA (OSE:AZT) will present at
Handelsbanken’s Small & Mid Cap Seminar 2025 in Stockholm taking place today, 04
June 2025.
…

Vis børsmeldingen

Estimated start of the presentation will be at 11.20 CET Speaker will be CEO,
Michael Akoh Please find the presentation enclosed

For further information:
Børge Sørvoll
CFO
+47 950 90 187
ir@arcticzymes.com

Kilde

[Staylong]

Ny denne fra hjemmesiden:

[tooeasy891]

Finally

[TekBot]

ArcticZymes Technologies Launches GMP-Grade Nuclease for Next-Generation Viral Vector Manufacturing.

Tromsø, Norway, June 16th, 2025 - ArcticZymes Technologies ASA (OSE:AZT) is
pleased to announce the expansion of its GMP product range, with the
introduction of M-SAN HQ GMP, a new GMP grade nuclease specifically designed for
…

Vis børsmeldingen

viral vector manufacturing. This new product combines the proven performance of
M-SAN HQ with the regulatory robustness of GMP manufacturing, providing a highly
effective solution for enzymatic host cell DNA removal under physiological salt
conditions

Unlike traditional nucleases, M-SAN HQ retains high activity at physiological
salt concentrations (~150 mM), enabling direct use in cell culture media or
harvest supernatants without harsh buffer exchanges. This makes it well-suited
for the manufacture of fragile viral vectors such as lentiviruses and
retroviruses, which are critical components of many advanced therapies and
vaccine platforms.

With the launch of M-SAN HQ GMP, viral vector manufacturers can now benefit from
the unmatched performance of M-SAN HQ, while ensuring a seamless transition into
full-scale production.

With the emergence of new therapeutic strategies, such as in vivo CAR-T, the
need to reduce nuclease and host cell DNA contamination in the final product is
even more critical. M-SAN HQ GMP is perfectly positioned to answer this need,
supporting the therapies of the future.

CEO Michael B. Akoh comments:
"With the launch of M-SAN HQ GMP, we’re bringing an important new product to the
market-an enzyme that performs optimally under physiological salt conditions and
meets GMP requirements, ensuring companies can quickly and easily move from
product development into full scale production.

This new product is a direct response to customer needs for technically advanced
and compliant nuclease that fit seamlessly into demanding biomanufacturing
workflows. It demonstrates ArcticZymes’ ongoing commitment to enabling the
success of advanced therapeutic developers."

M-SAN HQ GMP will be available to ordering from June 16th, 2025

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Its headquarters are based in Tromsø, Norway, at the SIVA Science Park.
ArcticZymes Technologies’ IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website:?www.arcticzymes.com

Kilde

[theroger]

@Staylong

Ny denne fra hjemmesiden:

Pent!

[Staylong]

Litt graving i påvente av neste oppdatering eller kvartalsrapport fra selskapet.
Hvilke CDMO’er har produksjonsprosesser som vil ha utbytte av å integrere SAN/M-SAN?
ChatGPT har svart.

Known CDMOs Working with SAN/M‑SAN

Oxford Biomedica

• Presented at ESGCT 2024 on advanced nuclease applications in LV bioprocessing , highlighting SAN’s effectiveness in improving downstream recovery and product quality patheon.com+9arcticzymes.com+9arcticzymes.com+9.

Undisclosed “key life‑science CDMO partners”

• ArcticZymes reported that several CDMOs are actively evaluating SAN & M‑SAN , with positive initial feedback and OEM discussions expected by late Q4 2024 or Q1 2025 arcticzymes.com.

Likely Early Adopters Based on Platform Fit

These CDMOs have purification workflows well-suited for integrating salt‑active nucleases:

• Lonza – With high‑salt affinity chromatography steps in AAV/LV purification, they’re well-positioned to benefit from salt‑stable nuclease performance criver.com.
• Yposkesi – AAV platforms using affinity resin followed by high-salt elution present a strong match for SAN/M‑SAN to aid DNA clearance yposkesi.com+1arcticzymes.com+1.
• Charles River – Their nAAVigation® platform uses chromatography post-harvest, likely benefiting from enhanced nucleases in high-salt clean-up stages criver.com+1criver.com+1.
• Patheon (Thermo Fisher) – Utilizes multi-mode purification workflows with chromatography steps well-suited to integration of salt-active enzymes arcticzymes.com+2patheon.com+2arcticzymes.com+2.
• PackGene – Includes residual nuclease clearance as part of AAV downstream processes, indicating capacity to adopt SAN/M‑SAN .

Integration Benefits for CDMOs

• High-salt stability : SAN/M‑SAN thrive in >200 mM NaCl, fitting seamlessly into existing AAV/LV cleanup protocols.
• Higher recovery, lower contaminants : Demonstrated improvements in vector purity and yield during chromatory lonza.com+2arcticzymes.com+2ubrigene.com+2.
• Regulatory readiness : GMP-grade (SAN HQ GMP) status and traceable enzyme approval streamline compliance arcticzymes.com.

Summary Table

CDMO	Platform Focus	SAN/M‑SAN Interest
Oxford Biomedica	LV bioprocessing	Actively presented data using SAN arcticzymes.com+1packgene.com+1
Key CDMOs via ArcticZymes	AAV & LV	Evaluating SAN/M‑SAN; OEM talks underway
Lonza	AAV & LV	High-salt chromatography fits SAN/M‑SAN integration
Yposkesi	AAV	Affinity + high-salt resin workflows
Charles River	nAAVigation, Lentivation	Chromatography-based cleanup pipelines
Patheon (Thermo Fisher)	AAV, LV	Customizable purification offerings
PackGene	AAV	Nuclease removal steps already included

[tooeasy891]

Bare som litt confirmation bias om at SAN blir mer brukt ser jeg det hittil i år er publisert flere forskningsartikler om SAN en i hele fjor. 14 mot 13stk.

[Staylong]

Jaja, det er jo ikke sånn at vi har så mye å gå på i mellom kvartalene. Det kan se ut som om de har vurdert det til at de ikke melder avtaler som innebærer å integrere (M-)SAN inn i prosessene til CDMO’er. De meldte Fujifilm-avtalen for en god stund tilbake uten at man klarer å spore den direkte tilbake i regnskapene. Jeg håper de siste integreringene av produkter hos CDMO’er vil gi markant langvarig løft i forbruket av SAN. Jeg tror jo egentlig det da jeg fortsatt er godt investert. For første gang siden våren 2020 og covid-perioden ser jeg lyst igjen på fremtiden. Covid visste man ville være midlertidig, men håpet var jo at de i neste omgang skulle gi større synergier til de andre produktene og SAN. Dette tok lengre tid enn man håpet på, men sånn er det jo veldig ofte.

[Savepig]

Snart done med å sette en bunn og snu oppover?

[Savepig]

Brudd over 20, så ser AZT lovende ut altså

[Zydenboy]

Er de derre svenskene som La Bull og de andre fortsatt inne i aksjen? Jeg har ikke fulgt med her på flere år.

[tooeasy891]

Ja, største aksjonær og i valgkomiteen.

[Do2Do]

To take-aways fra Q1 presentasjon 8. mai

Og her mener vel CEO viktig kunde typ Thermo Ficher?

[TekBot]

ArcticZymes Technologies ASA: Invitation to presentation of Q2 and 6M 2025 results

The Company will host a virtual Q2 and 6M 2025 presentation for investors,
analysts and media at 08:30 CET on Thursday, 14 August, 2025.

…

Vis børsmeldingen

The presentation will be given by CEO, Michael Akoh, VP Sales, Paul Blackburn
and CFO, Børge Sørvoll.

The presentation can be followed as a live webcast from Hegnar TV
on https://channel.royalcast.com/webcast/hegnarmedia/20250814_2 or
www.arcticzymes.com. It will be possible to post questions through the webcast
console.

The report for Q2 and 6M 2025 will be available on www.newsweb.no and on the
company’s homepage www.arcticzymes.com from 07.00 CET on Thursday, 14 August,
2025.

For further information, please contact:
CFO
Børge Sørvoll
ir@arcticzymes.com
+47 952 90187

Kilde

[TekBot]

ArcticZymes Technologies Reports Q2 and H1 2025 Results: Biomanufacturing Growth Accelerates as Customer centric Strategy Gains Momentum

Tromsø, Norway, August 14, 2025 - ArcticZymes Technologies (OSE: AZT) today
announced its financial results for the second quarter of 2025, highlighting
progress in the Company’s commercial transformation. Total revenues reached NOK
…

Vis børsmeldingen

28.9 million, up 5% year-over-year, led by strong 52% growth in the
Biomanufacturing segment which contributed NOK 18.1 million. The quarter also
marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a
product developed in direct response to customer needs. M-SAN HQ GMP enables
broader integration into viral vector manufacturing and reinforces ArcticZymes’
role as a reliable partner in gene therapy workflows.

Key Financials (Q2 and H1 2025):

· Total revenue: NOK 28.9 million, up 5% from NOK 27.5 million in Q2 2024. H1
2025 total revenues are at NOK 53.8 million, down 7% from NOK 57.6 million in H1
2024.
· Sales revenue: NOK 26.8 million, up 1%, compared to NOK 26.5 million in the
same quarter last year. H1 2025 sales are at NOK 50.0 million, down 13% from NOK
56.5 million in H1 2024.
· Revenue mix: Biomanufacturing contributed 68% (NOK 18.1 million); Molecular
Tools 32% (NOK 8.8 million) in Q2 2025
· EBITDA: Up 50% to NOK 3.9 million (Q2 2024: NOK 2.6 million). H1 2025 EBITDA
at NOK 0.1 (H1 2024: NOK 4.9 million).

Business Segment highlights

· Biomanufacturing momentum:
· Q2 2025 sales reached NOK 18.1 million, up 52% year-over-year (Q2 2024:
NOK 11.9 million) and 33% quarter-over-quarter (Q1 2025: NOK 13.6 million). H1
2025 Biomanufacturing revenues totalled NOK 31.4 million, a 32% increase over H1
2024 (NOK 23.6 million), marking the strongest first-half performance since
2022.
· Growth was driven by increased adoption of M-SAN HQ, continued onboarding
of new customers, and early integration into CDMO production workflows - all
reflecting strong execution of AZT’s customer-centric strategy.

· M-SAN HQ GMP launched:
· Unlocking future high-value opportunities in gene therapy and viral vector
production
· First commercial orders shipped to customers

· Product mix:
· M-SAN HQ became the Company’s top-selling product with a 62% increase over
the previous highest quarter and 130% growth over last year

· CDMO traction:
· AZT recognized initial revenues from a CDMO partner integrating M-SAN into
its production protocol

· Molecular Tools:
· Revenues declined 42% year-over-year and 11% sequentially, reflecting the
temporary absence of orders from a key customer.
· Encouragingly, this customer placed new purchase orders totalling nearly
NOK 16 million from Q3 and onwards, with deliveries and revenue recognition
scheduled across the next three quarters supporting a recovery in the second
half of the year.

CEO Commentary

“Q2 marked continued execution of our customer-centric strategy - one rooted in
partnership, providing solutions, and supporting our customers in achieving
their goals,” said Michael Akoh, CEO of ArcticZymes Technologies. "In
Biomanufacturing, we’re seeing growing adoption as more customers integrate our
Salt Active Nucleases into their workflows. The successful launch of GMP-grade M
-SAN HQ is a clear example of how we’re responding to customer needs - providing
a product they can rely on from early research through to the commercialization
of their therapies. It has already unlocked new opportunities and is helping
deepen our role as a long-term partner.

“In Molecular Tools, while one key customer paused orders earlier in the year,
we’re encouraged by their renewed commitment, including NOK 16 million in new
orders to be executed in the coming quarters, as well as growth from other
accounts. These results reflect not just strong execution, but real progress in
becoming a trusted partner to our customers - and in building a business
positioned for sustainable, long-term value creation for shareholders,” said
Michael Akoh, CEO of ArcticZymes Technologies.

Outlook

For the second half of 2025, ArcticZymes anticipates:

· Continued momentum in Biomanufacturing
· Further adoption of GMP-grade M-SAN HQ and SAN HQ neo GMP
· Expanded engagement with platform CDMOs expected to start showing real
momentum in 2026 and onwards
· Recovery in Molecular Tools revenues supported by a robust order backlog

With a healthy cash position, no debt, and a growing commercial pipeline, the
Company remains focused on commercial execution, operational discipline,
strategic innovation, and delivering sustainable, profitable growth.

-Ends-

Presentation and Webcast
The Company will host a virtual Q2 and H1 2025 presentation for investors,
analysts and media at 8:30 CET on Thursday, August 14, 2025.

The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll and VP
Sales and Marketing Paul Blackburn.

The presentation can be followed as a live webcast from Hegnar TV on
https://channel.royalcast.com/webcast/hegnarmedia/20250814_2 or
www.arcticzymes.com. It will be possible to post questions through the webcast
console.

The report for Q2 and 1H 2025 will be available on www.newsweb.no and on the
company’s homepage www.arcticzymes.com from 07.00 CET on Thursday, August 14,
2025.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel:+47 95 29 01 87

ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005. Its headquarters are based in
Tromsø, Norway, at the SIVA Science Park.

ArcticZymes Technologies’ IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com

Kilde

[tooeasy891]

Ser jo veldig bra ut, SAN med 50% vekst til 18m NOK, og den store Molecular Tools kunden bestilt for 16mnok i q3, som blir spredt over de neste 3 kvartaler.
Da man nok fint regne med et sterkt H2 her med SAN som omsetter for kanskje 20m+ og MT tilbake på ca 15mnok+

[Helt1]

Regne med. Håpe på. Anta. Ta et bet.

[Triotech]

Aiaiai, får litt våren 2020-vibber nå Denne kan fort komme tilbake til 40-50 nå (tror jeg, DYOR etc).

Svært gledelig at TMO nå har plassert en ordre de neste 3 kvartalene på 16m også

Deilig at biomanufacturing får traction, det er denne delen vi skal leve av fremover